STOCK TITAN

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB), a company dedicated to therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 am ET. A Q&A session will follow the presentation. Institutional investors can book meetings with management through their J.P. Morgan representatives. A live webcast will be available on the company’s Investors page, along with an archived replay for 30 days.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET. Following the prepared remarks, Mr. Ganot will be available for Q&A.

Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Biosciences
607-423-3219
clowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com


FAQ

What is Solid Biosciences' stock symbol?

Solid Biosciences is traded under the stock symbol SLDB.

When will Ilan Ganot present at the J.P. Morgan Healthcare Conference?

Ilan Ganot will present on January 13, 2022, at 9:00 am ET.

How can I watch the Solid Biosciences presentation?

You can watch the presentation live via the Events page on Solid Biosciences' website.

What disease does Solid Biosciences focus on?

Solid Biosciences is focused on treatments for Duchenne muscular dystrophy.

What are Solid Biosciences' lead gene therapy candidates?

Solid Biosciences' lead gene therapy candidates are SGT-001 and SGT-003.

Solid Biosciences Inc.

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Stock Data

198.57M
39.96M
0.82%
93.12%
4.59%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CHARLESTOWN